Bulletin of Experimental Biology and Medicine

, Volume 162, Issue 3, pp 383–386 | Cite as

Comparative Study of Antitumor Efficiency of Intraperitoneal and Intravenous Cytostatics in Experimental Rats with Disseminated Ovarian Cancer

  • V. G. Bespalov
  • E. A. Vyshinskaya
  • I. N. Vasil’eva
  • A. L. Semenov
  • M. A. Maidin
  • N. V. Barakova
  • A. N. Stukov
Article
  • 34 Downloads

Antitumor efficiencies of cytostatics dioxadet, cisplatin, mitomycin C, melphalan, and paclitaxel after a single intraperitoneal or intravenous injection in doses of 1.5, 4, 1.5, 2, and 5 mg/kg, respectively, were studied on the model of transplanted ovarian tumor in 124 rats. The antitumor effects were evaluated by the increase in median survival. Dioxadet, cisplatin, and melphalan injected intraperitoneally significantly prolonged the lifespan median – by 79, 88, and 114%, respectively, and were in fact ineffective, when injected intravenously. Intraperitoneal mitomycin C prolonged lifespan median by just 35%, intravenous – by 152%. Paclitaxel injected intraperitoneally and intravenously prolonged the lifespan median by 45 and 81%, respectively.

Key Words

ovarian cancer intraperitoneal chemotherapy antitumor drugs 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bespalov VG, Belyaeva OA, Kireeva GS, Senchik KYu, Stukov AN, Aristova VA, Vyshinskaya EA, Konkov SA, Krylova IA, Semenov AL, Maydin MA, Alexandrov VA, Belyaev AM. Antitumor effect of dioxadet in intraperitoneal chemoperfusion treatment for advanced ovarian cancer in experimental setting. Vopr. Onkol. 2014;60(2):72-79. Russian.Google Scholar
  2. 2.
    Bespalov VG, Belyaeva OA, Panchenko AV, Stukov AN, Gershanovich ML, Murazov YaG, Konkov SA, Kilmaeva NE, Krylova IM, Mironyuk TA, Latipova DKh. Antitumor activity of dioxadet compared with cisplatin activity in ascitic ovarian tumor rat model. Vopr. Onkol. 2011;57(6):771-774. Russian.Google Scholar
  3. 3.
    Adikesavan AK, Jaiswal AK. Thioredoxin-like domains required for glucose regulatory protein 58 mediated reductive activation of mitomycin C leading to DNA cross-linking. Mol. Cancer Ther. 2007;6(10):2719-2727.CrossRefPubMedGoogle Scholar
  4. 4.
    Blinman P, Gainford C, Donoghoe M, Martyn J, Blomfield P, Grant P, Kichenadasse G, Vaughan M, Brand A, Shannon C, Gebski V, Stockler M, Friedlander M. Feasibility, acceptability and preferences for intraperitoneal chemotherapy with paclitaxel and cisplatin after optimal debulking surgery for ovarian and related cancers: an ANZGOG study. J. Gynecol. Oncol. 2013;24(4):359-366.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Cristea M, Han E, Salmon L, Morgan RJ. Practical considerations in ovarian cancer chemotherapy. Ther. Adv. Med. Oncol. 2010;2(3):175-187.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Echarri Gonzales MJ, Green R, Muggia FM. Intraperitoneal drug delivery for ovarian cancer: why, how, who, what, and when? Oncology (Williston Park). 2011;25(2):156-165.Google Scholar
  7. 7.
    Galluzzi L, Vitale I, Michels J, Brenner C, Szabadkai G, Harel-Bellan A, Castedo M, Kroemer G. Systems biology of cisplatin resistance: past, present and future. Cell Death Dis. 2014;5. e1257. doi: 10.1038/cddis.2013.428.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Hasovits C, Clarke S. Pharmacokinetics and pharmacodynamics of intraperitoneal cancer chemotherapeutics. Clin. Pharmacokinet. 2012;51(4):203-224.CrossRefPubMedGoogle Scholar
  9. 9.
    Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA: Cancer J. Clin. 2011;61(3):183-203.Google Scholar
  10. 10.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: Cancer J. Clin. 2011;61(2):69-90.Google Scholar
  11. 11.
    Kampan NC, Madondo MT, McNally OM, Quinn M, Plebanski M. Paclitaxel and its evolving role in the management of ovarian cancer. Biomed. Res. Int. 2015;2015. e413076. doi: 10.1155/2015/413076.
  12. 12.
    Kemp Z, Ledermann J. Update on first-line treatment of advanced ovarian carcinoma. Int. J. Womens Health. 2013;5:45-51.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Yan TD, Cao CQ, Munkholm-Larsen S. A pharmacological review on intraperitoneal chemotherapy for peritoneal malignancy. World J. Gastrointest. Oncol. 2010;2(2):109-116.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  • V. G. Bespalov
    • 1
    • 2
  • E. A. Vyshinskaya
    • 1
  • I. N. Vasil’eva
    • 1
    • 2
  • A. L. Semenov
    • 1
    • 2
  • M. A. Maidin
    • 1
  • N. V. Barakova
    • 2
  • A. N. Stukov
    • 1
  1. 1.Research Laboratory of Cancer Chemoprophylaxis and OncopharmacologyI. N. Petrov Research Institute of Oncology, Ministry of Health of the Russian FederationSt. PetersburgRussia
  2. 2.International Research Centre “Biotechnologies of the Third Millennium”ITMO University (St. Petersburg National Research University of Information Technologies, Mechanics and OpticsSt. PetersburgRussia

Personalised recommendations